Colorectal Adenocarcinoma

P3, N=382, Not yet recruiting, Sun Yat-sen University

Expression of these targets correlated with favorable clinical outcomes in CRC patients. This work provides the first comprehensive mechanistic insight into antisense oligonucleotide-mediated miRNA suppression in Caco-2 colorectal adenocarcinoma cells and expands the miRNA target landscape.

An eight-gene CSC signature captures a stemness-linked G2/M program that generalizes across cohorts, relates to the microenvironment, and is therapeutically tractable via kinase targeting, providing a compact readout for risk stratification and preclinical screening.

We described the genomic landscape of KRASG12D-mutant CRC and PDAC, demonstrating that cases often have additional oncogenic alterations linked to resistance to KRAS inhibition. These alterations are also associated with a worse prognosis. Recognizing these alterations may inform new therapeutic strategies. Further studies are warranted to validate these findings in ongoing clinical trials.

LUNA is the first randomized study to evaluate the potential benefit of hepatectomy for patients with colorectal cancer with resectable liver and unresectable low-volume lung metastases. The trial was closed early and did not meet the primary endpoint. Findings from the as-treated analysis may warrant validation in a larger, multicenter cohort.

Colorectal adenocarcinoma cells in the urine may not only be large and tall columnar or vacuolated, but can also simulate HGUC cells or have small round or crescentic nuclei. Recognising this morphological diversity is important for accurate diagnosis.

Histopathological evaluation may aid risk stratification alongside KRAS status. Prognostic assessment in clinical settings should take both TNM staging and KRAS status into account.

Ultrastructural analysis revealed structural changes in the cytoplasm of fibroblasts suggestive of active membrane remodeling and fibroblast-myofibroblast transition, particularly at the tumor periphery. Collectively, these findings suggest that nCRT may be accompanied by a reorganization of the tumor stroma, leading to fibroblast activation, epithelial-mesenchymal transition, and vasculogenic mimicry, all of which could potentially contribute to tumor progression.

This pan-cancer study elucidates the pivotal role of ENTPD6 in tumor progression and establishes its potential as a therapeutic target for immunotherapeutic approaches in specific malignancies.

In contrast, SIRT1 expression was not significantly associated with these parameters. Both SIRT1 and SIRT2 showed a statistically significant relationship with K-RAS mutations, highlighting their potential roles in the molecular pathology of colorectal cancer.

However, there was a parallel drop in p62 expression, which indicates autophagy induction. AICAR increased the influence of WJ-CM on viability, as well as the levels of biomarkers associated with autophagy, phosphorylated  AMPK, and phosphorylated  mTOR in the HT-29 cells. WJ-CM inhibits colorectal cancer cell growth via activating AMPK/mTOR-mediated autophagy.

Comprehensive molecular profiling can help guide personalized immunotherapy decisions. Further studies are needed to confirm long-term benefits, optimize treatment duration and dosing, and identify predictive biomarkers for high-risk CRC.